Skip to main content
Psychedex
Article

MXiPr Facts

Dissociative; Arylcyclohexylamine; NMDA receptor antagonist

Description

MXiPr (methoxisopropamine) is a synthetic dissociative of the arylcyclohexylamine class. It blocks glutamate signaling in the brain,[1] producing the characteristic dissociative state.

Subjective effects include stimulation, bodily lightness, euphoria, dissociation, and a warm afterglow.[2] The experience unfolds in two phases — energizing lucidity giving way to deepening sensory disconnection, capped by warmth that can linger for hours.

MXiPr carries moderate dependence potential, and no lethal dose has been established in any species. The greatest danger is combining it with CNS depressants — opioids, alcohol, or benzodiazepines — which can suppress breathing to a fatal degree; every fatal case involving related compounds involved polydrug combinations.[3][4]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight10 – 20 mgCommon20 – 40 mgStrong40 – 60 mgHeavy60+ mg

Starts in 20 – 60 minLasts 2 – 5 hoursAfter-effects 4 – 48 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
10.5 days
Carries over to
ketamine; MXE; DMXE; MXPr; DCK; PCP; DXM; nitrous oxide

Effectslikely at a common dose

Perception
none likely · 23 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise
Body
none likely · 31 possible, including Motor control impairment, Dizziness, Nystagmus (eye wobbles)
Thinking
none likely · 27 possible, including Cognitive impairment, Confusion, Thought disorganization
Feeling
none likely · 6 possible, including Anxiety, Empathy suppression
Self
none likely · 6 possible, including Depersonalization, Derealization, Social disconnection
Time
none likely · 5 possible, including Temporal disorientation
Awareness
none likely · 3 possible

Who shouldn't take it

Absolute
Psychotic disorders; Concurrent MAOI use
Relative
Cardiovascular disease; CNS depressant co-administration; Seizure disorders; Hepatic impairment; Urological conditions; Pregnancy and lactation

Combinations61 recorded

Lethal (1)
GHB, GBL
Dangerous (30)
Antihistamines; Benzodiazepines; Benzodiazepines, Barbiturates; Buprenorphine, Kratom; Naltrexone; NSAIDs; Opioids; THC; Anticholinergics; Antipsychotics; Buspirone; Clonidine, Guanfacine; Dopamine agonists; Gabapentin, Pregabalin; GHB, Baclofen; Ibogaine; Ketamine, DXM, PCP; Lithium; Local anesthetics; MAOIs; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; and 6 more, see full page
Caution (24)
See full page: psychedex.org/substances/mxipr
Not graded (6)
Not listed never means safe.

Seek help immediately if

  • Severe disorientation; unable to move or speak (deep dissociation / "k-hole")
  • Complete loss of coordination — cannot stand or walk safely
  • Vomiting while incapacitated (choking / aspiration risk)
  • Very high blood pressure; fast heart rate
  • Slow or shallow breathing at high doses (especially mixed with depressants)
  • Unconsciousness; rarely, seizures

What to do

  1. Move them somewhere safe, away from stairs, water, roads, and sharp edges — they cannot protect themselves
  2. Place in the recovery position if vomiting or unconscious (aspiration is a key risk)
  3. Stay with them and reassure calmly; keep the environment quiet
  4. If breathing is slow/shallow or they are unresponsive, call emergency services
  5. Do not let them wander; do not leave them alone
  6. Be ready to give rescue breaths / CPR

Effects wear off with time in a safe, monitored setting. The main dangers are physical injury and aspiration while incapacitated, and respiratory depression when combined with other depressants — not the dissociation itself.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Irie T, Yanase Y, Demizu Y, Usami M, Kikura-Hanajiri R (2022) Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors — Journal of Pharmacological Sciences doi:10.1016/j.jphs.2022.09.005
  2. [2]
    ^(2024) Community-aggregated experience reports on MXiPr subjective effects and dosage Link
  3. [3]
    ^Theofel N, Möller P, Vejmelka E, Kastner K, Roscher S, Scholtis S, Tsokos M (2019) A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine — Journal of Analytical Toxicology doi:10.1093/jat/bky063
  4. [4]
    ^Riess S, Chèze M, Muckensturm A, Klinger N, Roussel O, Cirimele V (2024) 2-Fluorodeschloroketamine consumption: About two deaths and a case of self-mutilation — Journal of Analytical Toxicology doi:10.1093/jat/bkae021
Print version
Report an issue